NLM Digital Collections

Search

Start Over Subjects Economics, Pharmaceutical ✖Remove constraint Subjects: Economics, Pharmaceutical Subjects Humans ✖Remove constraint Subjects: Humans

11. Medicare Part D

Author(s):
Steiner, David J., author
Publication:
[Toronto, Ontario] : Thomson Reuters, 23-December-2019
Subject(s):
Drug Costs
Medicare Part D -- economics
Medicare Part D -- legislation & jurisprudence
Biosimilar Pharmaceuticals -- economics
Cost Control -- legislation & jurisprudence
Drugs, Generic -- economics
Economics, Pharmaceutical
Financing, Personal
Fraud
Legislation, Drug
Medicare Part C
Opioid-Related Disorders
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

12. Prescription Drug User Fee Act waivers, reductions, and refunds for drug and biological products

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, October 2019
Subject(s):
Drug Approval -- economics
Drug Approval -- legislation & jurisprudence
Investigational New Drug Application -- legislation & jurisprudence
Diffusion of Innovation
Economics, Pharmaceutical
Orphan Drug Production -- economics
Public Health
Small Business
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.
United States.

13. One percent of drugs with Medicaid reimbursement were not FDA-approved

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, May 2019
Subject(s):
Drug Approval
Insurance, Health, Reimbursement -- economics
Insurance, Health, Reimbursement -- statistics & numerical data
Medicaid -- economics
Medicaid -- statistics & numerical data
Economics, Pharmaceutical
Fraud -- prevention & control
Prescription Drugs -- economics
Humans
United States
United States. Food and Drug Administration.

14. Medicare Part B drug payments: impact of price substitutions based on 2017 average sales prices

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, August 2019
Subject(s):
Cost Control
Cost Savings
Drug Costs
Insurance, Health, Reimbursement
Medicare Part B -- economics
Reimbursement Mechanisms
Economics, Pharmaceutical
Humans
United States
Centers for Medicare & Medicaid Services (U.S.)